SEATTLE--(BUSINESS WIRE)--Shape Therapeutics, Inc. (ShapeTx), a development-stage biotechnology company leading the field of RNA-editing gene therapy, announces $35.5M in Series A financing, led by New Enterprise Associates (NEA), with additional participation from CureDuchenne Ventures. The new capital will enable the company to extend its growing portfolio of intellectual property, recruit and hire top scientific talent and advance its groundbreaking RNA and protein targeting platforms focused on curing human diseases.
These platforms include the proprietary ShapeTx RNAfix technology that enables direct in vivo targeting and modification of RNA by leveraging proteins such as Adenosine Deaminases Acting on RNA (ADARs), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). The RNAfix platform differentiates from other contemporary genome engineering technologies by engaging natural human cellular machinery to modify RNA.
ShapeTx was founded on the work of Dr. Prashant Mali, Assistant Professor of Bioengineering at UCSD, who during his postdoctoral fellowship in the George Church laboratory at Harvard Medical School pioneered the use of CRISPR in human cells. ShapeTx RNAfix platform is built upon his lab's most recent work demonstrating in vivo use of guide RNAs to recruit native ADARs and to fix mutations in multiple rare genetic disease mouse models.
Our technology can correct mutations or target specific genes in neurodegenerative, oncology, metabolic and rare genetic disorders by hijacking naturally occurring proteins such as ADARs present in our cells using just a short guide RNA. Our proprietary new platform avoids the risk of in vivo immunogenicity and permanent off-target damages commonly associated with CRISPR-based approaches, explained Francois Vigneault, Ph.D., President and CEO, who was previously VP of Research at Juno Therapeutics after a successful co-acquisition of AbVitro, Inc. by Juno and Celgene.
Ed Mathers, Partner at NEA and Board member at ShapeTx, said, One rarely comes across a proprietary technology platform with such transformative potential led by a focused and data-driven scientific group with a successful track record in pre-clinical and clinical development. The team has shown us an exciting demonstration of the technology in multiple in vivo models, alongside one of the strongest IP estates we have seen in the field. NEA looks forward to backing the company in future rounds as they move the technology toward the clinic.
While the ShapeTx platform will be enabling for many other genetic diseases, Dr. Malis in vivo proof of concept in Duchenne Muscular Dystrophy was quite exciting and could potentially lead to a cure for families suffering from such a debilitating disorder, said Debra Miller, CEO and Founder of CureDuchenne and CureDuchenne Ventures.
The ShapeTx Series A financing coincides with the formation of a world-class Scientific Advisory Board comprised of foremost global experts in genomics, bioengineering, and gene editing, including George Church Ph.D., James Collins Ph.D., and Don Cleveland Ph.D. The scientific advisory board will serve as strategic advisors and ensure that the research and development of its platforms meet the highest standards of scientific merit.
Prashant and Francois are some of the most innovative and brilliant individuals that have come through my lab over the years, and it will be impressive to see these two disrupt the field of gene therapy with this paradigm-shifting technology, said Dr. George Church, Professor in Genetics at Harvard Medical School and member of the ShapeTx Scientific Advisory board.
Shape Therapeutics Scientific Advisory Board Members:
George Church, Ph.D.
George Church Ph.D., world-famous geneticist, molecular engineer, and chemist. He developed the methods used for the first genome sequence & million-fold cost reductions since, as well as pioneered many of the CRISPR advances in genome editing. He is currently a Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.
James Collins, Ph.D.
James Collins Ph.D., is one of the pioneers of the field of synthetic biology and has made multiple synthetic biology and bioengineering breakthroughs in biotechnology and biomedicine. He serves as the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a member of the Harvard-MIT Health Sciences & Technology Faculty, and core member of the Wyss Institute. His many awards include a Rhodes Scholarship, a MacArthur Genius Award, a National Institutes of Health Directors Pioneer Award. Jim is also an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine, the American Academy of Arts & Sciences, as well as a charter fellow of the National Academy of Inventors.
Don Cleveland Ph.D.
Don Cleveland Ph.D. is an award-winning inventor and pioneer in the field of Antisense Oligonucleotide (ASO) and their uses in gene therapy. He was recently awarded the Breakthrough Prize in Life Sciences for his work on the pathogenesis of disease and ASO-mediated treatment approaches in ALS and Huntingtons disease. Don is currently Professor of Medicine and Department Chair of Cellular and Molecular Medicine and Neurosciences at the University of California at San Diego, and Head, Laboratory for Cell Biology at the San Diego branch of Ludwig Cancer Research. He has made pioneering discoveries on the mechanisms of chromosome movement and cell-cycle control during normal cellular division, as well as the principles of neuronal cell development and the relationship to defects that contribute to inherited neurodegenerative disease.
About Shape Therapeutics, Inc.
Shape Therapeutics, Inc. is creating the worlds leading RNA and protein targeting platforms focused on the cure of human diseases. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). The RNAfix technology allows for the editing of RNA using natural human cellular machinery, limiting the risk associated with immunogenicity, cellular toxicity, or off-target DNA editing. The teams founders include Prashant Mali, Ph.D., Francois Vigneault, Ph.D., and John Suliman. ShapeTx is headquartered in Seattle, Washington, with a satellite site opening in Cambridge, Massachusetts. For additional information, visit http://www.ShapeTx.com.
About NEA
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With more than $20 billion in cumulative committed capital since the firm's founding in 1978, NEA invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 225 portfolio company IPOs and more than 375 acquisitions. For additional information, visit http://www.nea.com.
About CureDuchenne Ventures
CureDuchenne Ventures supports Duchenne research by using philanthropic donations to encourage the development of new Duchenne drugs. Through an impact financing model, we can provide equity or royalty financing to biotech and pharmaceutical companies. CureDuchennes portfolio includes 16 wide-ranging projects with several successful exits. Investments from CureDuchenne Ventures have successfully de-risked and leveraged more than $2.3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne. For additional information, visit https://www.cureduchenne.org/ventures/.
See the original post:
Shape Therapeutics, Inc. Raises $35.5M Series A Financing, Led by NEA and Announces the Formation of a World-Class Scientific Advisory Board, to...
- Molecular Genetics Testing - StatPearls - NCBI Bookshelf - November 16th, 2024
- Working with Molecular Genetics (Hardison) - Biology LibreTexts - November 16th, 2024
- Molecular Underpinnings of Genetic and Rare Diseases: From ... - Frontiers - November 16th, 2024
- The molecular genetics of schizophrenia: New findings promise new insights. - November 16th, 2024
- 8: Techniques of Molecular Genetics - Biology LibreTexts - September 4th, 2024
- 1.5: Molecular Genetics - Biology LibreTexts - September 4th, 2024
- Molecular genetics made simple - PMC - National Center for ... - September 4th, 2024
- 4 Introduction to Molecular Genetics - University of Minnesota Twin Cities - September 4th, 2024
- Molecular genetics - Definition and Examples - Biology Online - September 4th, 2024
- A Detailed Look at the Science of Molecular Genetics - KnowYourDNA - September 4th, 2024
- Molecular Genetics | NHLBI, NIH - September 4th, 2024
- Molecular biology - Wikipedia - September 4th, 2024
- Genetics, Molecular & Cellular Biology Admissions - September 4th, 2024
- Researchers map 50,000 of DNAs mysterious knots in the human genome - EurekAlert - September 4th, 2024
- Artificial selection of mutations in two nearby genes gave rise to shattering resistance in soybean - Nature.com - September 4th, 2024
- Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany - Marketscreener.com - April 7th, 2023
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 11th, 2022
- People don't mate randomly but the flawed assumption that they do is an essential part of many studies linking genes to diseases and traits - The... - November 25th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - October 7th, 2022
- NIPD Genetics: Leading Genetic Testing Company - October 7th, 2022
- Skeletal Biology and Regeneration Students Recognized For Research Excellence - UConn Today - University of Connecticut - October 7th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 7th, 2022
- Every Body's Talking at Them: an Interview with Jon Lieff - CounterPunch - October 7th, 2022
- TriBeta invites students to explore opportunities to work with faculty at research fair on Oct. 11 - Ohio University - October 7th, 2022
- Genetics: the Vatican Does Not Intend to Be Behind the Times - FSSPX.News - October 7th, 2022
- Yield10 Bioscience Appoints Willie Loh, Ph.D., to the Board of Directors - citybiz - October 7th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 7th, 2022
- Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel - Yahoo Finance - October 7th, 2022
- UTHSC Researcher Co-Leads Study of Genes that Modulate Aging, Lifespan - UTHSC News - UTHSC News - October 7th, 2022
- GATC Health Investor Conference to Feature First Public Demonstration of Its AI Platform's Drug Discovery Capabilities - PR Newswire - October 7th, 2022
- Three Professors Conferred Tenure and Eleven Promoted - Wesleyan Argus - October 7th, 2022
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 7th, 2022
- Dalhousie to present exhibition celebrating Gerhard Herzberg and his legacy - Dal News - October 7th, 2022
- Why Some People Should Rethink Their Morning Cup Of Coffee - Health Digest - October 7th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 7th, 2022
- UofL researchers lead the call to increase genetic diversity in immunogenomics - uoflnews.com - July 6th, 2021
- In Brief This Week: Foundation Medicine, Myriad Genetics, Genetron Health, and More - GenomeWeb - July 6th, 2021
- More filling? Tastes great? How flies, and maybe people, choose their food - Yale News - July 6th, 2021
- Genetic mapping of subsets of patients with fragile X syndro | TACG - Dove Medical Press - July 6th, 2021
- What is The Babydust Method? Danielle Lloyd swears method helped her conceive girl - The Mirror - July 6th, 2021
- Datar Cancer Genetics joins hands with US based Iylon Precision Oncology to offer personalized Precision Oncology cancer treatment solutions - PR Web - July 6th, 2021
- Mapping a pathway to competitive production - hortidaily.com - hortidaily.com - July 6th, 2021
- Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. - Physician's Weekly - July 6th, 2021
- Global Genomics Market | Rising Incidence of Chronic and Genetic Diseases are Key Factors to Grow Market During 2021-2029 | 23andMe, Agilent... - July 6th, 2021
- The Babydust Method Danielle Lloyd used to conceive a girl after four sons and how it works - RSVP Live - July 6th, 2021
- In the beginning science and faith - The Irish Times - June 24th, 2021
- Ancient Maya Maintained Native Tropical Forest Plants around Their Water Reservoirs | Archaeology - Sci-News.com - June 24th, 2021
- Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health - June 24th, 2021
- Xlife Sciences AG: Collaboration with the University of Marburg - Yahoo Finance - June 24th, 2021
- Genetics diagnostics in India is on the verge of transformation: Neeraj Gupta, Founder and CEO of Genes2me - The Financial Express - June 24th, 2021
- Precision Medicine: Improving Health With Personalized Solutions - BioSpace - June 24th, 2021
- Half of Portland areas 22 top National Merit winners hail from just 2 schools - OregonLive - June 24th, 2021
- Investing in stem cells, the building blocks of the body - MoneyWeek - June 24th, 2021
- New study finds low levels of a sugar metabolite associates with disability and neurodegeneration in multiple sclerosis - Newswise - May 14th, 2021
- Cernadas-Martn Is a Champion for Marine and Human Diversity | | SBU News - Stony Brook News - May 14th, 2021
- Four Penn Faculty: Election to the National Academy of Sciences - UPENN Almanac - May 14th, 2021
- Is there a difference between a gene-edited organism and a 'GMO'? The question has important implications for regulation - Genetic Literacy Project - May 14th, 2021
- 5 Students Inducted Into American Society for Biochemistry and Molecular Biology Honor Society - Wesleyan Connection - May 14th, 2021
- The Science of Aliens, Part 2: What Kind of Genetic Code Would Extraterrestrials Have? - Air & Space Magazine - May 14th, 2021
- UT Austin Faculty Member Receives 2021 Piper Professor Award - Office of the Executive Vice President and Provost - UT News | The University of Texas... - May 14th, 2021
- Distinguished University of Birmingham plant scientist elected to the Royal Society - University of Birmingham - May 14th, 2021
- Double Hoo Research: Undergrads and Grads Team Up to Create Knowledge - University of Virginia - May 14th, 2021
- Global Genetic Testing Market Top Countries Analysis and Manufacturers With Impact of COVID-19 | 2021-2028 Detail Analysis focusing on Application,... - May 14th, 2021
- Morag Park named to the Order of Quebec - McGill Reporter - McGill Reporter - May 14th, 2021
- Third Rock Ventures Launches Flare Therapeutics With $82 Million Series A - BioSpace - May 14th, 2021
- The Royal Society announces election of new Fellows 2021 - Cambridge Network - May 14th, 2021
- Researchers Decode the "Language" of Immune Cells - Technology Networks - May 14th, 2021
- RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map -... - May 14th, 2021
- Mice Sperm Sabotage Other Swimmers With Poison | Smart News - Smithsonian Magazine - February 14th, 2021
- Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth - Newswise - February 14th, 2021
- Devious sperm 'poison' their rivals, forcing them to swim in circles until they die - Livescience.com - February 14th, 2021
- More needs to be done to find and fight COVID-19 variants, says Colorado researcher - FOX 31 Denver - February 14th, 2021
- Selfish sperm genes 'poison' the competition for the win - Big Think - February 14th, 2021
- Some sperm cells swim faster and even poison their competition to climb to the top - ZME Science - February 14th, 2021
- We are scientists: U of T researchers reach out to girls and women around the world - News@UofT - February 14th, 2021
- Mutations in frogs point to autism genes' shared role in neurogenesis - Spectrum - February 14th, 2021
- Global Genetic Testing Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper -... - February 14th, 2021
- Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL Under Fed Conditions - GlobeNewswire - February 14th, 2021
- GeneSight Psychotropic Test's Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels... - February 14th, 2021
- Gu Ailing Eileen: I've learned to win for myself, not other people - Olympic Channel - February 14th, 2021